RBC Capital on Axsome Therapeutics (AXSM): 'Still See Upside On ADA Approval And Launch'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $219.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
